Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265798 · ClinicalTrials.gov registry record · Phase 2
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
A Phase 2 study of Gastrointestinal Stromal Tumor, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 6
- Study locations
NCT00265798 is a Phase 2 study of Gastrointestinal Stromal Tumor that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 38 participants, below the 65-participant average among 8 other Gastrointestinal Stromal Tumor trials with a reported enrollment target (42% lower). The trial reports 6 study locations across 3 states.
The verdict
NCT00265798, a Phase 2 study of Gastrointestinal Stromal Tumor, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 6
- Study locations
Study Summary
This phase II trial is studying how well sorafenib works in treating patients with malignant gastrointestinal stromal tumor that progressed during or after previous treatment with imatinib mesylate and sunitinib malate. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Conditions Studied
Interventions
- DRUG Sorafenib Tosylate
Study Locations (6)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
- Decatur Memorial Hospital - Decatur
- Central Illinois Hematology Oncology Center - Springfield
California
- City of Hope Comprehensive Cancer Center - Duarte
- University of California Davis Comprehensive Cancer Center - Sacramento
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2005-09-14 |
| Est. Completion | 2026-03-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265798
The ClinicalTrials.gov registry entry for NCT00265798 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 65-participant average among 8 other Gastrointestinal Stromal Tumor trials with a reported enrollment target (42% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Stromal Tumor appearing as the primary indexed condition, and to 1 intervention - of which Sorafenib Tosylate is the first listed.
NCT00265798 reports 6 study locations spanning 3 distinct geographic areas - top geographies include Illinois, California, New York.
Frequently Asked Questions
What is clinical trial NCT00265798 about?
NCT00265798 is a clinical study titled "Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate". This phase II trial is studying how well sorafenib works in treating patients with malignant gastrointestinal stromal tumor that progressed during or after previous treatment with imatinib mesylate and sunitinib malate. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes nee...
What is the current status of trial NCT00265798?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2005-09-14. Estimated completion is 2026-03-19.
What conditions does trial NCT00265798 study?
This clinical trial studies the following conditions: Gastrointestinal Stromal Tumor.
What interventions are being tested in trial NCT00265798?
The interventions under investigation include: Sorafenib Tosylate (DRUG).
Who is sponsoring clinical trial NCT00265798?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00265798 being conducted?
This trial has 6 study locations across California, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Stromal Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
COMPLETED · Phase 2
-
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery
COMPLETED · Phase 2
-
Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor
COMPLETED · Phase 2
-
Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood
COMPLETED · Phase 2
-
Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.